On October 26, 2017 MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, reported that it will present three posters highlighting both new clinical findings and preclinical research accomplishments at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held October 26 – 30, 2017 in Philadelphia, Pennsylvania (Press release, MabVax, OCT 26, 2017, View Source [SID1234521221]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Paul Maffuid, Ph.D., Executive Vice President of Research and Development of MabVax, stated, “We look forward to sharing the significant progress we have made through these clinical and preclinical investigations. We will report new clinical data from our ongoing Phase 1 clinical trial and report on our most advanced preclinical program that demonstrates our growing expertise in the development of fully human antibodies targeting carbohydrate antigens expressed on many solid tumor cancers.”
The Company will present the following posters during the meeting:
Presenting Author: Paul Maffuid, Ph.D., Executive Vice President Research and Development, MabVax Therapeutics
Title: Using CA19-9 as a translational biomarker for sLea targeted agents MVT-5873 and MVT-1075 in cancer
Date & Time: Saturday, October 28, 2017 at 12:30 PM
Session: Poster Session A: Biomarkers
Location: Hall E, Pennsylvania Convention Center
Poster No.: 62
Abstract No.: A062
The poster summarizes preclinical development activities including a survey of CA19-9 positive cancers in patient tissue microarrays and patient sera samples treated with the anti-CA19-9 antibody MVT-5873 with potential utility as a translational biomarker.
Presenting Author: Paul Maffuid, Ph.D., Executive Vice President Research and Development, MabVax Therapeutics
Title: Preliminary Phase 1 data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer
Date & Time: Sunday, October 29, 2017 at 12:30 PM
Session: Late Breaking Poster Session B: Therapeutic Agents: Biological
Location: Hall E, Pennsylvania Convention Center
Poster No.: LB-25
Abstract No.: LB-B25
The poster summarizes interim data from the ongoing Phase 1 trial of MVT-5873 used as a single agent and in combination with a first line therapy in newly diagnosed patients with CA19-9 positive pancreatic cancer.
Presenting Author: G. Jonah Rainey, Ph.D., Executive Director Antibody Research, MabVax Therapeutics
Title: A therapeutic antibody candidate against the broadly expressed Tn and sTn carbohydrate cancer antigens
Date & Time: Sunday, October 29, 2017 at 12:30 PM
Session: Poster Session B: Therapeutic Agents: Biological
Location: Hall E, Pennsylvania Convention Center
Poster No.: 104
Abstract No.: B104
The poster summarizes the discovery, optimization, and target validation for the Company’s fully human antibodies targeting the Thomsen-nouveau (Tn) and the sialyl Tn (sTn) carbohydrate antigens for patients with ovarian and breast cancers.